Labcorp Earnings Call Highlights Growth, Investment, Risks

Labcorp Holdings Inc. ((LH)) has held its Q4 earnings call. Read on for the main highlights of the call.

Labcorp Holdings Inc. struck an upbeat tone on its latest earnings call, underscoring a business that is growing, expanding margins and investing heavily in innovation. Management acknowledged pockets of pressure in early development and a one-off hit to volumes, but argued that strong backlog, disciplined capital allocation and clear 2026 growth plans leave the company well positioned.

Full-Year Growth and Profitability Gains

Labcorp reported 2025 enterprise revenue growth of more than 7% year over year, with adjusted EPS climbing about 13% for the full year. Margin performance was another bright spot, as adjusted operating margins expanded by more than 50 basis points, reflecting better mix, productivity and cost discipline across the portfolio.

Solid Q4 Performance Caps the Year

Fourth‑quarter 2025 revenue reached $3.5 billion, up 5.6% from a year earlier, including 3.8% organic growth. Adjusted operating income rose to $488 million, or 13.9% of revenue, versus 12.7% in the prior year, driving an 18% jump in adjusted EPS to $4.07.

Diagnostics Segment Delivers Broad-Based Strength

Diagnostics continued to anchor results, with Q4 revenue of $2.7 billion rising 5.5% and organic growth of 4.1%. Volume increased 2.2% while price and mix added 3.3%, supporting a 150‑basis‑point improvement in adjusted operating margin to 15.4% and higher segment operating income of $419 million.

Central Labs and Biopharma Momentum

In Biopharma Laboratory Services, Central Labs stood out with revenue up 11.1% in the quarter, or 7.7% in constant currency. The segment posted a healthy book‑to‑bill of 1.16 in the quarter and 1.09 over the trailing 12 months, while backlog ended Q4 at $8.7 billion with about $2.7 billion expected to turn into revenue over the next year.

Cash Generation Fuels Capital Allocation

Labcorp generated $1.2 billion of free cash flow for the year, an increase of 10% despite some quarterly timing swings. In Q4 alone it invested $258 million in acquisitions, repurchased $225 million of stock and paid $59 million in dividends, and it closed the year with roughly $800 million of remaining share repurchase authorization.

Strategic Deals Expand the Network

Management highlighted a string of hospital and regional asset transactions that are adding scale and reach to the diagnostics franchise. Recent deals include Parkview select outreach, Community Health Systems outreach assets, Incyte Diagnostics anatomic pathology assets and Empire City Labs assets, collectively contributing to more than $1 billion of revenue growth from such arrangements over three years.

Innovation Engine Accelerates

Product and technology investment remains a key growth driver, with more than 130 new tests launched in 2025 across oncology, women’s health, neurology and autoimmune disease. Esoteric testing volume grew at a double‑digit rate and Labcorp’s share in that category climbed from 37.5% in early 2023 to 41.5% by Q4 2025, helped by new offerings such as an FDA‑cleared blood test for Alzheimer’s and expanded minimal residual disease testing.

AI, Automation and Digital Expansion

The company is also leaning into automation and AI to support scale and margin expansion, including initiatives in pathology, cytology and microbiology. It further broadened its direct‑to‑consumer OnDemand platform to over 200 biomarkers and advanced an automated mass spectrometry partnership with Roche, aimed at boosting high‑throughput, specialized testing capabilities.

Guidance Signals Continued Growth in 2026

For 2026, Labcorp guided to enterprise revenue growth of 4.7% to 6.0%, with Diagnostics expected to rise 5% to 6% and Biopharma Laboratory Services up 3% to 5%. Adjusted EPS is projected between $17.65 and $18.25, implying roughly 9% growth at the midpoint, alongside free cash flow of $1.24 billion to $1.36 billion and ongoing LaunchPad savings of $100 million to $125 million annually.

Early Development Remains a Pressure Point

The main weak spot is Early Development within BLS, where Q4 revenue dropped 13.5% and 15.1% in constant currency. Management is trimming and refocusing this business, planning to remove roughly $50 million of lower‑margin annual revenue to improve operating income, with most restructuring actions expected to be largely complete by the end of the second quarter of 2026.

Temporary Q4 Volume Softness

Organic diagnostic volume growth in Q4 was softer than underlying demand trends, contributing only about 1.1% to the 2.2% total volume increase. Executives pointed to reduced referrals from a large consumer genetics customer experiencing financial difficulties and disruptive winter weather, and they characterized the client‑related impact as a one‑time event with volumes already beginning to recover.

Free Cash Flow Timing and Working Capital

Quarterly free cash flow dipped to $490 million from $665 million a year earlier, primarily because of working capital timing that pulled forward some cash outflows. Management emphasized that the full‑year picture is more telling, with free cash flow up 10% and strong enough to support both elevated capital expenditures and continued shareholder returns.

PAMA and Policy Overhangs

Regulatory and reimbursement uncertainty remains a risk, with PAMA reform again delayed through the end of 2026 and no permanent solution yet in place. Labcorp continues to advocate for legislative fixes while noting that previously discussed potential annual savings of $25 million to $30 million from favorable PAMA outcomes remain an open variable rather than a near‑term catalyst.

Stepped-Up Capex and New Central Lab Facility

Capital spending is expected to rise to about 4% of revenue in 2026 as the company builds a new strategic central lab and kit production campus exceeding 500,000 square feet. Management acknowledged that this elevated investment could affect the cadence of free cash flow in the near term but framed the project as critical infrastructure for long‑term growth in global central lab services.

ACA Tax Credit Expiration Creates a Small Drag

The expiration of certain ACA exchange tax credits is expected to modestly weigh on diagnostic volumes in 2026, with a projected impact of roughly 30 basis points. Labcorp has already incorporated this headwind into its guidance assumptions and will monitor patient enrollment and test utilization trends as the policy change flows through.

Labcorp’s earnings call painted a picture of a business balancing structural growth and margin expansion with a few manageable headwinds. While softness in early development, higher capex and policy uncertainty bear watching, strong diagnostics momentum, robust central lab backlog, rising cash generation and a confident 2026 outlook leave the company sounding cautiously optimistic for investors focused on durable earnings growth.